- Home
- SPRO vs LSB Comparison
SPRO vs LSB Comparison
Compare SPRO & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- LSB
- Stock Information
- Founded
- SPRO 2013
- LSB 2002
- Country
- SPRO United States
- LSB China
- Employees
- SPRO N/A
- LSB N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- LSB
- Sector
- SPRO Health Care
- LSB
- Exchange
- SPRO Nasdaq
- LSB NYSE
- Market Cap
- SPRO 45.7M
- LSB 53.6M
- IPO Year
- SPRO 2017
- LSB N/A
- Fundamental
- Price
- SPRO $0.83
- LSB $2.23
- Analyst Decision
- SPRO Buy
- LSB
- Analyst Count
- SPRO 4
- LSB 0
- Target Price
- SPRO $5.00
- LSB N/A
- AVG Volume (30 Days)
- SPRO 217.5K
- LSB 7.3K
- Earning Date
- SPRO 03-12-2025
- LSB 12-19-2024
- Dividend Yield
- SPRO N/A
- LSB N/A
- EPS Growth
- SPRO N/A
- LSB N/A
- EPS
- SPRO 0.06
- LSB N/A
- Revenue
- SPRO $106,455,000.00
- LSB $79,415,311.00
- Revenue This Year
- SPRO N/A
- LSB $39.33
- Revenue Next Year
- SPRO N/A
- LSB $75.61
- P/E Ratio
- SPRO $12.71
- LSB N/A
- Revenue Growth
- SPRO 37.01
- LSB N/A
- 52 Week Low
- SPRO $0.74
- LSB $1.88
- 52 Week High
- SPRO $1.89
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- SPRO 44.07
- LSB 40.56
- Support Level
- SPRO $0.82
- LSB $2.10
- Resistance Level
- SPRO $0.85
- LSB $2.49
- Average True Range (ATR)
- SPRO 0.05
- LSB 0.22
- MACD
- SPRO 0.01
- LSB 0.00
- Stochastic Oscillator
- SPRO 43.33
- LSB 16.35
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.